Genomic Valley Biotech reported a return to profitability for the financial year ended March 31, 2026, with a net profit of ₹3,03,041 compared to a net loss of ₹35,60,932 in the previous year. The company's revenue from operations declined significantly to ₹26,75,000 in FY26 from ₹84,39,394 in FY25. For the quarter ended March 31, 2026, the company recorded a net loss of ₹81,745 on revenue from operations of ₹3,75,000.

Financial Performance

The turnaround in annual profitability was driven by a reduction in total expenses, which fell to ₹22,74,590 in FY26 from ₹40,69,678 in FY25. Employee benefits expense for the year decreased to ₹10,59,000 from ₹12,08,645 in the prior year, while depreciation and amortization expense increased to ₹37,064 from ₹25,414. Other expenses rose to ₹11,78,525 in FY26 compared to ₹8,21,824 in the previous year.

Quarterly Results

For the quarter ended March 31, 2026, the company reported a loss before tax of ₹15,624. Total expenses for the quarter stood at ₹3,59,376. In comparison, the quarter ended March 31, 2025, saw a net loss of ₹8,34,895 on total revenue of ₹26,35,770. The tax expense for the quarter included a current tax of ₹1,00,000 and a deferred tax adjustment of -₹2,631.

Board Appointments

The Board of Directors approved the appointment of Mr. Navjyoti Kumar Jha as the Internal Auditor of the company for the financial year 2026-27. Mr. Jha brings 26 years of experience and holds a Bachelor of Commerce degree. He is not related to any director of the company.

Financial Position

The company's total assets as of March 31, 2026, stood at ₹4,24,95,674, slightly lower than ₹4,35,65,624 in the previous year. Total equity increased to ₹3,92,84,574 from ₹3,89,81,533. Trade receivables rose to ₹2,31,77,445 from ₹2,21,44,945, while cash and cash equivalents decreased to ₹42,936 from ₹2,28,976.

The statutory auditors, M/s ANDROS & Co. Chartered Accountants, issued an unmodified opinion on the audited standalone financial results.

Genomic Valley Biotech Limited has notified BSE of an upcoming board meeting, scheduled for Friday, May 29, 2026, at its registered office located at 4 KM Stone, Berri Chhara Road, Tanda Heri, Tehsil Bahadurgarh, District Jhajjar, Haryana. The intimation, dated May 18, 2026, was filed by Managing Director Yogesh Agrawal under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Agenda for the Board Meeting

The board meeting has been convened to transact the following key business items, subject to the permission of the Chair:

Trading Window Closure

In accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company's internal code for prevention of insider trading, the trading window for dealing in the securities of Genomic Valley Biotech has been closed. The closure applies to Directors, Key Managerial Personnel (KMPs), Promoters, Promoter Group members, and other Designated Persons covered under the code.

The key details of the trading window closure are as follows:

The filing was digitally signed by Yogesh Agrawal, Managing Director (DIN: 01165288), on May 18, 2026.